The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
August 19th 2025
The complete response letter (CRL) stated that vatiquinone's new drug application (NDA) did not provide substantial evidence of efficacy and would need to be evaluated in a new trial.
Hyperkalemia Treatment May Require New Dosing Instructions
October 26th 2015The FDA is requiring Concordia Pharmaceuticals to conduct studies on its hyperkalemia treatment, sodium polystyrene sulfonate (Kayexalate), to see if it binds to other medications administered by mouth, which would decrease potency.
Read More